BACKGROUND: Leptospira species cause leptospirosis, a zoonotic disease found worldwide. Current vaccines against leptospirosis provide protection only against closely related serovars. METHODS: We evaluated an attenuated transposon mutant of Leptospira interrogans serovar Manilae (M1352, defective in lipopolysaccharide biosynthesis) as a live vaccine against leptospirosis. Hamsters received a single dose of vaccine and were challenged with the homologous serovar (Manilae) and a serologically unrelated heterologous serovar (Pomona). Comparisons were made with killed vaccines. Potential cross-protective antigens against leptospirosis were investigated. RESULTS: Live M1352 vaccine induced superior protection in hamsters against homologous challenge. The live vaccine also stimulated cross-protection against heterologous challenge, with 100% survival (live M1352) versus 40% survival (killed vaccine). Hamsters receiving either vaccine responded to the dominant membrane proteins LipL32 and LipL41. Hamsters receiving the live vaccine additionally recognized LA3961/OmpL36 (unknown function), Loa22 (OmpA family protein, recognized virulence factor), LA2372 (general secretory protein G), and LA1939 (hypothetical protein). Manilae LigA was recognized by M1352 vaccinates, whereas LipL36 was detected in Pomona. CONCLUSION: This study demonstrated that a live, attenuated vaccine can stimulate cross-protective immunity to L. interrogans and has identified antigens that potentially confer cross-protection against leptospirosis.
BACKGROUND:Leptospira species cause leptospirosis, a zoonotic disease found worldwide. Current vaccines against leptospirosis provide protection only against closely related serovars. METHODS: We evaluated an attenuated transposon mutant of Leptospira interrogans serovar Manilae (M1352, defective in lipopolysaccharide biosynthesis) as a live vaccine against leptospirosis. Hamsters received a single dose of vaccine and were challenged with the homologous serovar (Manilae) and a serologically unrelated heterologous serovar (Pomona). Comparisons were made with killed vaccines. Potential cross-protective antigens against leptospirosis were investigated. RESULTS: Live M1352 vaccine induced superior protection in hamsters against homologous challenge. The live vaccine also stimulated cross-protection against heterologous challenge, with 100% survival (live M1352) versus 40% survival (killed vaccine). Hamsters receiving either vaccine responded to the dominant membrane proteins LipL32 and LipL41. Hamsters receiving the live vaccine additionally recognized LA3961/OmpL36 (unknown function), Loa22 (OmpA family protein, recognized virulence factor), LA2372 (general secretory protein G), and LA1939 (hypothetical protein). Manilae LigA was recognized by M1352 vaccinates, whereas LipL36 was detected in Pomona. CONCLUSION: This study demonstrated that a live, attenuated vaccine can stimulate cross-protective immunity to L. interrogans and has identified antigens that potentially confer cross-protection against leptospirosis.
Authors: Dieter M Bulach; Richard L Zuerner; Peter Wilson; Torsten Seemann; Annette McGrath; Paul A Cullen; John Davis; Matthew Johnson; Elizabeth Kuczek; David P Alt; Brooke Peterson-Burch; Ross L Coppel; Julian I Rood; John K Davies; Ben Adler Journal: Proc Natl Acad Sci U S A Date: 2006-09-14 Impact factor: 11.205
Authors: James Matsunaga; Miranda Lo; Dieter M Bulach; Richard L Zuerner; Ben Adler; David A Haake Journal: Infect Immun Date: 2007-03-19 Impact factor: 3.441
Authors: Marcia Gamberini; Ricardo M Gómez; Marina V Atzingen; Elizabeth A L Martins; Silvio A Vasconcellos; Eliete C Romero; Luciana C C Leite; Paulo L Ho; Ana L T O Nascimento Journal: FEMS Microbiol Lett Date: 2005-03-15 Impact factor: 2.742
Authors: Jarlath E Nally; Julian P Whitelegge; Sara Bassilian; David R Blanco; Michael A Lovett Journal: Infect Immun Date: 2006-11-13 Impact factor: 3.441
Authors: Everton F Silva; Marco A Medeiros; Alan J A McBride; Jim Matsunaga; Gabriela S Esteves; João G R Ramos; Cleiton S Santos; Júlio Croda; Akira Homma; Odir A Dellagostin; David A Haake; Mitermayer G Reis; Albert I Ko Journal: Vaccine Date: 2007-06-14 Impact factor: 3.641
Authors: Mathieu Picardeau; Dieter M Bulach; Christiane Bouchier; Richard L Zuerner; Nora Zidane; Peter J Wilson; Sophie Creno; Elizabeth S Kuczek; Simona Bommezzadri; John C Davis; Annette McGrath; Matthew J Johnson; Caroline Boursaux-Eude; Torsten Seemann; Zoé Rouy; Ross L Coppel; Julian I Rood; Aurélie Lajus; John K Davies; Claudine Médigue; Ben Adler Journal: PLoS One Date: 2008-02-13 Impact factor: 3.240
Authors: Paula Ristow; Pascale Bourhy; Flávia Weykamp da Cruz McBride; Claudio Pereira Figueira; Michel Huerre; Patrick Ave; Isabelle Saint Girons; Albert I Ko; Mathieu Picardeau Journal: PLoS Pathog Date: 2007-07 Impact factor: 6.823
Authors: Amy M King; Thanatchaporn Bartpho; Rasana W Sermswan; Dieter M Bulach; Azad Eshghi; Mathieu Picardeau; Ben Adler; Gerald L Murray Journal: Infect Immun Date: 2013-05-20 Impact factor: 3.441
Authors: Lisa M Esteves; Sara M Bulhões; Claudia C Branco; Francisco M Mota; Clara Paiva; Rita Cabral; Maria Luisa Vieira; Luisa Mota-Vieira Journal: PLoS One Date: 2014-09-25 Impact factor: 3.240
Authors: Janet C Lindow; Elsio A Wunder; Stephen J Popper; Jin-Na Min; Praveen Mannam; Anup Srivastava; Yi Yao; Kathryn P Hacker; Khadir Raddassi; Patty J Lee; Ruth R Montgomery; Albert C Shaw; Jose E Hagan; Guilherme C Araújo; Nivison Nery; David A Relman; Charles C Kim; Mitermayer G Reis; Albert I Ko Journal: PLoS Pathog Date: 2016-11-03 Impact factor: 6.823
Authors: Carolina Lessa-Aquino; Janet C Lindow; Arlo Randall; Elsio Wunder; Jozelyn Pablo; Rie Nakajima; Algis Jasinskas; Jaqueline S Cruz; Alcineia O Damião; Nívison Nery; Guilherme S Ribeiro; Federico Costa; José E Hagan; Mitermayer Galvão Reis; Albert I Ko; Marco Alberto Medeiros; Philip L Felgner Journal: PLoS Negl Trop Dis Date: 2017-01-31
Authors: S K Behera; T C Sabarinath; Y Deneke; S K Bansal; K Mahendran; A Kumar; K Senthil; M R Verma; S ChandraSekar; S Atif Ali Journal: Iran J Vet Res Date: 2021 Impact factor: 1.376